| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| C R Young, J G Longhurst, M B Bowers, C M Mazur. The expanding indications for clozapine. Experimental and clinical psychopharmacology. vol 5. issue 3. 1997-09-22. PMID:9260069. |
clozapine is increasingly being used for clinical indications in addition to treatment-resistant schizophrenia; this article reviews the relevant literature. |
1997-09-22 |
2023-08-12 |
Not clear |
| R R Conley, W T Carpenter, C A Tamming. Time to clozapine response in a standardized trial. The American journal of psychiatry. vol 154. issue 9. 1997-09-18. PMID:9286183. |
the authors sought to determine the time to clozapine response in treatment-refractory patients with schizophrenia. |
1997-09-18 |
2023-08-12 |
Not clear |
| R Rosenheck, J Cramer, W Xu, J Thomas, W Henderson, L Frisman, C Fye, D Charne. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. The New England journal of medicine. vol 337. issue 12. 1997-09-18. PMID:9295240. |
a comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. |
1997-09-18 |
2023-08-12 |
Not clear |
| R Rosenheck, J Cramer, W Xu, J Thomas, W Henderson, L Frisman, C Fye, D Charne. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. The New England journal of medicine. vol 337. issue 12. 1997-09-18. PMID:9295240. |
department of veterans affairs cooperative study group on clozapine in refractory schizophrenia. |
1997-09-18 |
2023-08-12 |
Not clear |
| R Rosenheck, J Cramer, W Xu, J Thomas, W Henderson, L Frisman, C Fye, D Charne. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. The New England journal of medicine. vol 337. issue 12. 1997-09-18. PMID:9295240. |
clozapine, a relatively expensive antipsychotic drug, is widely used to treat patients with refractory schizophrenia. |
1997-09-18 |
2023-08-12 |
Not clear |
| D J Healy, J H Meador-Woodruf. Clozapine and haloperidol differentially affect AMPA and kainate receptor subunit mRNA levels in rat cortex and striatum. Brain research. Molecular brain research. vol 47. issue 1-2. 1997-09-17. PMID:9221932. |
these dissimilarities may represent an interesting mechanism for some of the differential therapeutic or toxic effects of clozapine and haloperidol, and also may be relevant to our understanding of dopamine-glutamate interactions in schizophrenia. |
1997-09-17 |
2023-08-12 |
rat |
| P F Buckley, Z Y Ibrahim, B Singer, B Orr, K Donenwirth, P S Bra. Aggression and schizophrenia: efficacy of risperidone. The journal of the American Academy of Psychiatry and the Law. vol 25. issue 2. 1997-08-28. PMID:9213289. |
in this regard, clozapine has been particularly effective in reducing aggressive behavior in patients with schizophrenia. |
1997-08-28 |
2023-08-12 |
Not clear |
| O Freudenreich, R D Weiner, J P McEvo. Clozapine-induced electroencephalogram changes as a function of clozapine serum levels. Biological psychiatry. vol 42. issue 2. 1997-08-19. PMID:9209730. |
specific electroencephalogram (eeg) changes during clozapine therapy were prospectively studied in a cohort of 50 chronic state hospital patients with schizophrenia who were randomly assigned to one of three nonoverlapping clozapine serum level ranges (50-150 ng/ml, 200-300 ng/ml, and 350-450 ng/ml). |
1997-08-19 |
2023-08-12 |
Not clear |
| E Schulz, C Fleischhaker, H E Remschmid. Correlated changes in symptoms and neurotransmitter indices during maintenance treatment with clozapine or conventional neuroleptics in adolescents and young adults with schizophrenia. Journal of child and adolescent psychopharmacology. vol 6. issue 2. 1997-08-15. PMID:9231304. |
correlated changes in symptoms and neurotransmitter indices during maintenance treatment with clozapine or conventional neuroleptics in adolescents and young adults with schizophrenia. |
1997-08-15 |
2023-08-12 |
Not clear |
| E Schulz, C Fleischhaker, H E Remschmid. Correlated changes in symptoms and neurotransmitter indices during maintenance treatment with clozapine or conventional neuroleptics in adolescents and young adults with schizophrenia. Journal of child and adolescent psychopharmacology. vol 6. issue 2. 1997-08-15. PMID:9231304. |
these findings suggest involvement of norepinephrine and serotonin in the pathophysiology of schizophrenia (with depression associated with lower mhpg levels and negative symptoms associated with lower serotonin levels) and in the therapeutic actions of clozapine. |
1997-08-15 |
2023-08-12 |
Not clear |
| Y Kohn, R P Ebstein, U Heresco-Levy, B Shapira, L Nemanov, I Gritsenko, M Avnon, B Lere. Dopamine D4 receptor gene polymorphisms: relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 7. issue 1. 1997-07-23. PMID:9088883. |
dopamine d4 receptor gene polymorphisms: relation to ethnicity, no association with schizophrenia and response to clozapine in israeli subjects. |
1997-07-23 |
2023-08-12 |
human |
| Y Kohn, R P Ebstein, U Heresco-Levy, B Shapira, L Nemanov, I Gritsenko, M Avnon, B Lere. Dopamine D4 receptor gene polymorphisms: relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 7. issue 1. 1997-07-23. PMID:9088883. |
previous work has not found linkage or association of a polymorphism in exon 3 of this gene with diagnosis of schizophrenia or response to clozapine. |
1997-07-23 |
2023-08-12 |
human |
| B L Murphy, R H Roth, A F Arnste. Clozapine reverses the spatial working memory deficits induced by FG7142 in monkeys. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 16. issue 6. 1997-07-17. PMID:9165499. |
these results from nonhuman primates suggest that the clozapine doses commonly used to treat schizophrenia may not be optimal for treating the pfc cognitive deficits associated with this illness. |
1997-07-17 |
2023-08-12 |
rat |
| A M Mortime. Cognitive function in schizophrenia--do neuroleptics make a difference? Pharmacology, biochemistry, and behavior. vol 56. issue 4. 1997-07-07. PMID:9130306. |
atypical neuroleptics may, owing to their novel mechanisms of action, have the capacity to remediate cognitive impairment in schizophrenia: there is some evidence that clozapine has a "cognitive sparing" effect, but further research is needed in this area, particularly with other new drugs. |
1997-07-07 |
2023-08-12 |
Not clear |
| D E Fujii, I Ahmed, M Jokumsen, J M Compto. The effects of clozapine on cognitive functioning in treatment-resistant schizophrenic patients. The Journal of neuropsychiatry and clinical neurosciences. vol 9. issue 2. 1997-07-07. PMID:9144103. |
it was concluded that clozapine treatment is associated with global cognitive improvements in patients with treatment-resistant schizophrenia. |
1997-07-07 |
2023-08-12 |
Not clear |
| T Sumiyoshi, M Hasegawa, K Jayathilake, H Y Meltze. Prediction of short-term changes in symptom severity by baseline plasma homovanillic acid levels in schizophrenic patients receiving clozapine. Psychiatry research. vol 69. issue 2-3. 1997-07-03. PMID:9109179. |
the relationship between pretreatment levels of plasma homovanillic acid (phva) and the outcome of clozapine treatment was studied in 18 male patients with schizophrenia who were resistant to treatment with conventional neuroleptics. |
1997-07-03 |
2023-08-12 |
Not clear |
| T Sumiyoshi, M Hasegawa, K Jayathilake, H Y Meltze. Prediction of short-term changes in symptom severity by baseline plasma homovanillic acid levels in schizophrenic patients receiving clozapine. Psychiatry research. vol 69. issue 2-3. 1997-07-03. PMID:9109179. |
these results suggest that pretreatment levels of phva can be used to predict relatively short-term changes in the positive symptoms of patients with schizophrenia receiving clozapine treatment, particularly for clozapine responders. |
1997-07-03 |
2023-08-12 |
Not clear |
| A Meyer-Lindenberg, H Gruppe, U Bauer, S Lis, S Krieger, B Gallhofe. Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study. Pharmacopsychiatry. vol 30. issue 2. 1997-07-01. PMID:9131723. |
we report on a double-blind randomized study designed to evaluate the impact of zotepine and clozapine on cognitive dysfunction in schizophrenia. |
1997-07-01 |
2023-08-12 |
Not clear |
| A Meyer-Lindenberg, H Gruppe, U Bauer, S Lis, S Krieger, B Gallhofe. Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study. Pharmacopsychiatry. vol 30. issue 2. 1997-07-01. PMID:9131723. |
the study confirms previous results on the efficacy of clozapine and zotepine in treating negative symptoms of schizophrenia. |
1997-07-01 |
2023-08-12 |
Not clear |
| S A Chong, C H Tan, Y M Khoo, H S Lee, K E Wong, F Ngui, M Winslo. Clinical evaluation and plasma clozapine concentrations in Chinese patients with schizophrenia. Therapeutic drug monitoring. vol 19. issue 2. 1997-06-27. PMID:9108654. |
clinical evaluation and plasma clozapine concentrations in chinese patients with schizophrenia. |
1997-06-27 |
2023-08-12 |
Not clear |